In-Depth Investigation on Potential Mechanism of Forest-Grown Ginseng Alleviating Alzheimer's Disease via UHPLC-MS-Based Metabolomics

被引：0

作者：

Niu, Huazhou ^{[1
]}

Zhang, Meng ^{[1
]}

Zhang, Kaiyue ^{[1
]}

Aishan, Saibire ^{[1
]}

Li, Hui ^{[1
]}

Wu, Wei ^{[1
]}

机构：

[1] Changchun Univ Chinese Med, Jilin Ginseng Acad, Changchun 130117, Peoples R China

来源：

METABOLITES | 2025年 / 15卷 / 02期

关键词：

forest-grown ginseng; Alzheimer's disease; UHPLC-MS; metabolites; neuroinflammation; EXERCISE; RATS;

D O I：

10.3390/metabo15020093

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Background: Alzheimer's disease is a central nervous system degenerative disease closely related to age with a complex pathogenesis. As a natural medicinal plant, forest-grown ginseng (GSF) contains abundant ginsenosides and offers significant neuroprotective effects. Methods: In this study, we comprehensively investigated the effect of GSF on the cell viability of PC12 cells in an AD model alongside metabolic changes in the serum and brains of mice, combined with an efficacy evaluation of PC12 cells in vitro and UHPLC-MS-based metabolomics in vivo. The goal of this study is to clarify the potential mechanism of GSF in treating AD. Results: The PC12 cell results showed that GSF can promote the proliferation of PC12 cells, reduce the content of IL-8, increase the activity of SOD, and alleviate the inflammation and oxidative stress induced by A beta 25 similar to 35. The immunohistochemical results for the mouse brain tissue also showed that GSF could reduce the inflammatory response of mouse brain tissue by reducing the overexpression of IBa1. AD was alleviated by reducing A beta protein deposition in the mouse brain tissue. An untargeted metabolomics analysis was performed using UHPLC-Q-Exactive MS and principal component analysis (PCA) to identify the differentially expressed metabolites in the serum and brain tissue of AD mice after treatment. Twenty and seventeen different metabolites were identified in the serum and brain tissue, respectively. The pathway enrichment analysis of differential metabolites showed that GSF could treat AD by up-regulating succinic acid semialdehyde, carbamoyl phosphate, Sphingosine 1-phosphate, L-cystathionine, 2-ketobutyric acid, Vanillylmandelic acid, and D-Ribose to regulate sphingomyelin metabolism, the synthesis and metabolism of neurotransmitters and precursors, and energy metabolism. Conclusions: GSF can reduce neuroinflammation and alleviate Alzheimer's disease by regulating the metabolic disorders of amino acids, sphingolipids, unsaturated fatty acids, and arachidonic acid in mice serum and brain tissue metabolites. These results suggest a link between metabolite imbalance and AD, and reveal the basis for the mechanism of ginsenosides in AD treatment.

引用

页数：17

共 34 条

[1] Chen W., Balan P., Popovich D.G., Comparison of Ginsenoside Components of Various Tissues of New Zealand Forest-Grown Asian Ginseng (Panax ginseng) and American Ginseng (Panax quinquefolium L.), Biomolecules, 10, (2020)
[2] Hao M., Ding C., Peng X., Chen H., Dong L., Zhang Y., Chen X., Liu W., Luo Y., Ginseng under forest exerts stronger anti-aging effects compared to garden ginseng probably via regulating PI3K/AKT/mTOR pathway, SIRT1/NF-κB pathway and intestinal flora, Phytomedicine, 105, (2022)
[3] Wang H.P., Wang Z.J., Du J., Lin Z.Z., Zhao C., Zhang R., Yin Q., Fan C.L., Peng P., Wang Z.B., Comprehensive Identification of Ginsenosides in the Roots and Rhizomes of Panax ginseng Based on Their Molecular Features-Oriented Precursor Ions Selection and Targeted MS/MS Analysis, Molecules, 28, (2023)
[4] Ni X.C., Wang H.F., Cai Y.Y., Yang D., Alolga R.N., Liu B., Li J., Huang F.Q., Ginsenoside Rb1 inhibits astrocyte activation and promotes transfer of astrocytic mitochondria to neurons against ischemic stroke, Redox. Biol, 54, (2022)
[5] Liu X., Mi X., Wang Z., Zhang M., Hou J., Jiang S., Wang Y., Chen C., Li W., Ginsenoside Rg3 promotes regression from hepatic fibrosis through reducing inflammation-mediated autophagy signaling pathway, Cell Death Dis, 11, (2020)
[6] Li J., Gao W., Zhao Z., Li Y., Yang L., Wei W., Ren F., Li Y., Yu Y., Duan W., Et al., Ginsenoside Rg1 Reduced Microglial Activation and Mitochondrial Dysfunction to Alleviate Depression-Like Behaviour via the GAS5/EZH2/SOCS3/NRF2 Axis, Mol. Neurobiol, 59, pp. 2855-2873, (2022)
[7] Cheng H., Liu J., Zhang D., Wang J., Tan Y., Feng W., Peng C., Ginsenoside Rg1 Alleviates Acute Ulcerative Colitis by Modulating Gut Microbiota and Microbial Tryptophan Metabolism, Front. Immunol, 13, (2022)
[8] Kong L., Liu Y., Li J., Wang Y., Ji P., Shi Q., Han M., Xu H., Li W., Li W., Ginsenoside Rg1 alleviates chronic inflammation-induced neuronal ferroptosis and cognitive impairments via regulation of AIM2–Nrf2 signaling pathway, J. Ethnopharmacol, 330, (2024)
[9] Chu S., Gu J., Feng L., Liu J., Zhang M., Jia X., Liu M., Yao D., Ginsenoside Rg5 improves cognitive dysfunction and beta-amyloid deposition in STZ-induced memory impaired rats via attenuating neuroinflammatory responses, Int. Immunopharmacol, 19, pp. 317-326, (2014)
[10] Liu S., Fan M., Zheng Q., Hao S., Yang L., Xia Q., Qi C., Ge J., MicroRNAs in Alzheimer’s disease: Potential diagnostic markers and therapeutic targets, Biomed. Pharmacother, 148, (2022)

← 1 2 3 4 →